BMY Sep 2024 47.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.7200

-0.1400

(-16.28%)

As of 02:44PM EDT. Market open.

Loading interactive chart…

Zacks
Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
Business Wire
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
PRINCETON, N.J., June 04, 2024--Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or....
Simply Wall St.
Shareholders in Bristol-Myers Squibb (NYSE:BMY) are in the red if they invested a year ago
The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do...